Seagen Inc. will expand its Washington footprint, announcing plans to build a 270,000-square-foot complex in Everett, WA. Seagen expects to have the facility operational in 2024 as it looks for greater control and flexibility over the production of its medicines to treat cancer. 

The new biomanufacturing complex will be a modern production facility to make advanced antibody-based medicines for the commercial market and for use in clinical sites around the world.  

Clay Siegall, President and CEO of Seagen said in a news release, “In cancer research and development, Seagen must continue to be agile and flexible, especially in manufacturing, to advance our promising pipeline of medicines for people living with cancer and bring these medicines to patients as fast as possible.”